Safety and pharmacokinetics of recombinant factor XIII in healthy volunteers

Summary

Factor XIII (FXIII) is a plasma transglutaminase that covalently cross-links fibrin proteins to one another and to other proteins, increasing the mechanical strength of blood clots. Endogenous FXIII is the final enzyme in the clotting cascade and circulates as a heterotetramer comprising 2 FXIII-A subunits and 2 FXIII-B subunits. Recombinant human FXIII A₂ (rFXIII) homodimer is produced inSaccharomyces cerevisiae. Upon injection, rFXIII combines with the free FXIIIB subunit that circulates in excess to form the rA₂B₂ tetramer. In this placebo-controlled, doubleblind, multi-dose study, the safety, pharmacokinetics, and pharmacodynamics of rFXIII were studied in 24 healthy volunteers, who were randomized in 2 cohorts of 12 subjects each. In each cohort, 8 subjects received 5 daily intravenous doses of rFXIII (10 or 25 U/kg), and 4 subjects received placebo. Recombinant FXIII was well tolerated. No deaths or serious adverse events occurred. The type and frequency of adverse events showed no pattern or dose response. No clinically significant changes in haematology, serum chemistry, or urinalysis laboratory values were observed. No clinical coagulopathy or thrombosis was observed. Recombinant FXIII did not produce any anti-yeast or anti-FXIII antibodies. After 5 daily doses of rFXIII, accumulation indices indicated a 3 to 4fold accumulation of rFXIII in plasma. The elimination half-life, estimated for rFXIII as the heterotetramer, ranged from 228-346 hours for the 10U/kg dose group and 167-197 hours for the 25U/kg dose group. The safety, pharmacokinetic, and immunogenic profile of rFXIII suggests it may have potential use in patients with congenital or acquired FXIII deficiency

Keywords

Factor XIII - clinical trial - FXIII deficiency

• References

• 1 Egbring R, Kroniger A, Seitz R. Factor XIII deficiency: pathogenic mechanisms and clinical significance. Sem Thromb Hemost 1996; 22: 419-25.
• 2 Board PG, Losowsky MS, Miloszewski KJA. Factor XIII: inherited and acquired deficiency. Blood Reviews 1993; 7: 229-42.
• 3 McDonagh J. Structure and function of Factor XIII. Colman RW, Hirsh J, Marder VJ, Salzman EW. Hemostasis and Thrombosis.. Philadelphia PA: JB Lippincott; 1987: 289-300.
• 4 Hornyak TJ, Bishop PD, Shafer JA. Alpha-thrombin-catalyzed activation of human platelet factor XIII: relationship between proteolysis and factor XIIIa activity. Biochemistry 1989; 28: 7326-32.
• 5 Brackmann HH, Egbring R, Ferster A. et al. Pharmacokinetics and tolerability of factor XIII concentrates prepared from human placenta or plasma: a crossover randomised study. Thromb Haemost 1995; 74: 622-5.
• 6 Fear JD, Miloszewski KJA, Losowsky MS. The half life of factor XIII in the management of inherited deficiency. Thromb Haemost 1983; 49: 102-5.
• 7 Rodeghiero F, Morbin M, Barbui T. Subunit A of factor XIII regulates subunit B plasma concentration. Thromb Haemost 1981; 46: 621-2.
• 8 Saito M, Asakura H, Yoshida T. et al. A familial factor XIII subunit B deficiency. Br J Haematol 1990; 74: 290-4.
• 9 Yorifuji H, Anderson K, Lynch G W. et al. B protein of factor XIII: differentiation between free B and complexed B. Blood 1988; 72: 1645-50.
• 10 Reynolds TC, Butine MD, Visich J E. et al. Safety, pharmacokinetics, and immunogenicity of single dose rFXIII administration to healthy volunteers. J Thromb Haemost 2005; 3: 922-8.
• 11 Gootenberg JE. Factor concentrates for the treatment of factor XIII deficiency. Curr Opin Hematol 1998; 5: 372-5.
• 12 Grothaus-Pinke B, Gunzelmann S, Fauser A A. et al. Factor XIII replacement in stem cell transplant (SCT) recipients with severe graft-versus-host disease of the bowel: report of an initial experience. Transplantation 2001; 72: 1456-8.
• 13 Katona E, Haramura G, Karpati L. et al. A simple, quick one-step ELISA assay for the determination of complex plasma factor XIII (A2B2). Thromb Haemost 2000; 82: 268-73.
• 14 Ponce RA, Visich JE, Heffernan JK. et al. Preclinical safety and pharmacokinetics of recombinant human Factor XIII. Toxicol Pathol 2005; 33: 495-506.